AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1393807 — intervention group
Group type: EXPERIMENTAL
Intervention: Peribulbar injection (group 1)
Number of subjects: 79
Study 1393807 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrobulbar injection (group 2)
Number of subjects: 79
Study 2856908 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1.0 mg/kg X h)
Number of subjects: 9
Study 2856908 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (0.16 mg/kg X h)
Number of subjects: 9
Study 2856908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30782696 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy-led NIV sessions (5 sessions of 30 minutes each)
Number of subjects: 130
Study 30782696 — intervention group
Group type: COMPARATOR
Intervention: Continuous high-flow nasal oxygen therapy (usual care)
Number of subjects: 130
Study 30782696 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy-led NIV
Number of subjects: 130
Study 30782696 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen therapy
Number of subjects: 130
Study 29415145 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 0
Study 29415145 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 0
Study 29415145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26897504 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (3 interactive workshops on prevention of cardiovascular disease)
Number of subjects: 320
Study 26897504 — intervention group
Group type: COMPARATOR
Intervention: Control group (information by post)
Number of subjects: 320
Study 23957715 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant trastuzumab (12 months or 9 weeks)
Number of subjects: 1500
Study 23957715 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant trastuzumab
Number of subjects: 1500
Study 23957715 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant trastuzumab
Number of subjects: 1500
Study 22519853 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated mosquito nets (ITNs) protection from birth (group A)
Number of subjects: 3387
Study 22519853 — intervention group
Group type: COMPARATOR
Intervention: Insecticide-treated mosquito nets (ITNs) protection from age 6 months (group B)
Number of subjects: 3387
Study 22519853 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 3387
Study 20078802 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic suggestion
Number of subjects: 67
Study 20078802 — intervention group
Group type: COMPARATOR
Intervention: Story (prosody control)
Number of subjects: 67
Study 20078802 — intervention group
Group type: COMPARATOR
Intervention: Standard operating room noise
Number of subjects: 67
Study 18408389 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 100
Study 18408389 — intervention group
Group type: COMPARATOR
Intervention: Autologous rectus fascia sling
Number of subjects: 100
Study 15807809 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 25-35 years
Number of subjects: 80
Study 15807809 — intervention group
Group type: COMPARATOR
Intervention: Age group 50-65 years
Number of subjects: 80
Study 11961629 — intervention group
Group type: EXPERIMENTAL
Intervention: Local wound infiltration with 10 ml of 0.5% bupivacaine (group I, n = 50)
Number of subjects: 100
Study 11961629 — intervention group
Group type: COMPARATOR
Intervention: Instillation of the extraperitoneal space with 40 ml of 0.25% bupivacaine (group II, n = 50)
Number of subjects: 100
Study 11961629 — intervention group
Group type: COMPARATOR
Intervention: Group II (extraperitoneal instillation)
Number of subjects: 100
Study 10510158 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg)
Number of subjects: 20
Study 10510158 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (60 mg)
Number of subjects: 20
Study 10510158 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (80 mg)
Number of subjects: 20
Study 10510158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7493428 — intervention group
Group type: EXPERIMENTAL
Intervention: Water restriction (200 ml/day) during low-sodium diet
Number of subjects: 6
Study 7493428 — intervention group
Group type: COMPARATOR
Intervention: Hydrated group (1800 ml/day water intake) during low-sodium diet
Number of subjects: 6
Study 7493428 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (hydrated and dehydrated)
Number of subjects: 6
Study 1372508 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin (5 mu twice, 6 hours apart)
Number of subjects: 221
Study 1372508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 1372508 — intervention group
Group type: COMPARATOR
Intervention: No treatment (without penicillin or placebo)
Number of subjects: 221
Study 1372508 — intervention group
Group type: COMPARATOR
Intervention: Infants born soon after PROM
Number of subjects: 221
Study 1372508 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants born after prolonged PROM
Number of subjects: 221
Study 1372508 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 221
Study 3876579 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic electrical stimulation (AES)
Number of subjects: 25
Study 31290227 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience-based intervention programme
Number of subjects: 285
Study 31290227 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 285
Study 30325721 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient expression of emotions
Number of subjects: 79
Study 30325721 — intervention group
Group type: EXPERIMENTAL
Intervention: Companion questions about psychosocial and lifestyle topics
Number of subjects: 79
Study 30325721 — intervention group
Group type: EXPERIMENTAL
Intervention: RIAS overall patient-centeredness score
Number of subjects: 79
Study 27637570 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathe Right® external nasal dilator
Number of subjects: 15
Study 27637570 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbine® internal nasal dilator
Number of subjects: 15
Study 27637570 — intervention group
Group type: COMPARATOR
Intervention: No device (control)
Number of subjects: 15
Study 23713923 — intervention group
Group type: EXPERIMENTAL
Intervention: Translucent occlusion
Number of subjects: 0
Study 23713923 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightproof occlusion
Number of subjects: 0
Study 23713923 — intervention group
Group type: EXPERIMENTAL
Intervention: Both occlusion types
Number of subjects: 0
Study 23713923 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis
Number of subjects: 0
Study 21941790 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPPV
Number of subjects: 46
Study 21941790 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 46
Study 19135078 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimuli composed of spatially alternating stripes containing different luminances or motion signals
Number of subjects: 0
Study 19135078 — intervention group
Group type: EXPERIMENTAL
Intervention: Neon-color-spreading paradigm
Number of subjects: 0
Study 17148971 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole prophylaxis
Number of subjects: 534
Study 17148971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 534
Study 15480323 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for 2 years
Number of subjects: 186
Study 15480323 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for 1 year
Number of subjects: 186
Study 15480323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 11735682 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial injury prevention programme in soccer
Number of subjects: 0
Study 11735682 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle disk training combined with thorough warm-up in European team handball
Number of subjects: 0
Study 11735682 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle supports (semirigid orthoses or air-cast braces) in high-risk sports
Number of subjects: 0
Study 11735682 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock-absorbing insoles in footwear
Number of subjects: 0
Study 9059210 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous brachial plexus infusion of butorphanol 6 mg with 0.5% mepivacaine
Number of subjects: 2
Study 9059210 — intervention group
Group type: COMPARATOR
Intervention: Bolus of butorphanol 1 mg with 1.5% mepivacaine and continuous brachial plexus infusion of 0.5% mepivacaine with butorphanol 6 mg
Number of subjects: 2
Study 8440540 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 12
Study 8440540 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12
Study 8440540 — intervention group
Group type: COMPARATOR
Intervention: Intralipid infusion
Number of subjects: 12
Study 8440540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3512124 — intervention group
Group type: EXPERIMENTAL
Intervention: Moricizine (10 mg/kg/day)
Number of subjects: 50
Study 3512124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 3512124 — intervention group
Group type: EXPERIMENTAL
Intervention: Moricizine
Number of subjects: 50
Study 29353551 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages highlighting human responsibility with a distal temporal frame
Number of subjects: 355
Study 29353551 — intervention group
Group type: COMPARATOR
Intervention: Messages highlighting human responsibility with an imminent temporal frame
Number of subjects: 355
Study 29353551 — intervention group
Group type: COMPARATOR
Intervention: Messages highlighting animal responsibility
Number of subjects: 355
Study 26259053 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Hz TENS
Number of subjects: 81
Study 26259053 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 Hz TENS
Number of subjects: 81
Study 26259053 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 81
Study 24396838 — intervention group
Group type: EXPERIMENTAL
Intervention: Pink-veneered zirconia abutments and all-ceramic crowns
Number of subjects: 0
Study 24396838 — intervention group
Group type: COMPARATOR
Intervention: White zirconia abutments (control group)
Number of subjects: 0
Study 22429002 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint‐induced movement therapy (CIMT)
Number of subjects: 63
Study 22429002 — intervention group
Group type: COMPARATOR
Intervention: Bimanual training (BIM)
Number of subjects: 63
Study 22429002 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CIMT and BIM
Number of subjects: 63
Study 22429002 — intervention group
Group type: EXPERIMENTAL
Intervention: CIMT
Number of subjects: 63
Study 20631478 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 0
Study 20631478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18775020 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7371 20 mg
Number of subjects: 402
Study 18775020 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7371 5 mg
Number of subjects: 402
Study 18775020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study 18775020 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7371
Number of subjects: 402
Study 16214830 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine 7.5 mg bid
Number of subjects: 939
Study 16214830 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine 10 mg bid
Number of subjects: 939
Study 16214830 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine 5 mg bid
Number of subjects: 939
Study 16214830 — intervention group
Group type: COMPARATOR
Intervention: atenolol 50 mg od
Number of subjects: 939
Study 16214830 — intervention group
Group type: COMPARATOR
Intervention: atenolol 100 mg
Number of subjects: 939
Study 12023136 — intervention group
Group type: EXPERIMENTAL
Intervention: 125I (144 Gy)
Number of subjects: 82
Study 12023136 — intervention group
Group type: COMPARATOR
Intervention: 103Pd (125 Gy, NIST‐1999)
Number of subjects: 82
Study 10503809 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoguanidine (two dose levels)
Number of subjects: 599
Study 10503809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 599
Study 8604442 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive approach
Number of subjects: 57
Study 8604442 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive approach
Number of subjects: 57
Study 1777372 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 or 100 mg once daily)
Number of subjects: 18
Study 1777372 — intervention group
Group type: COMPARATOR
Intervention: Captopril (25 or 50 mg twice daily)
Number of subjects: 18
Study 6118768 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise training
Number of subjects: 129
Study 6118768 — intervention group
Group type: EXPERIMENTAL
Intervention: extra advice
Number of subjects: 129
Study 6118768 — intervention group
Group type: COMPARATOR
Intervention: normal treatment (control)
Number of subjects: 129
Study 31544381 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with comprehensive rehabilitation therapy
Number of subjects: 62
Study 31544381 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive rehabilitation therapy alone (Control group)
Number of subjects: 62
Study 27996217 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training (ET) program, 12-week, twice a week, 60-minute sessions
Number of subjects: 32
Study 27996217 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 32
Study 27996217 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training (ET) program
Number of subjects: 32
Study 25367691 — intervention group
Group type: EXPERIMENTAL
Intervention: R. emodi capsules (two times a day, two days before menstruation and continued for the first three days of menstruation)
Number of subjects: 45
Study 25367691 — intervention group
Group type: COMPARATOR
Intervention: Mefenamic acid capsules (three times a day on the same protocol)
Number of subjects: 45
Study 23652600 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete ST-segment resolution (>70%)
Number of subjects: 2484
Study 23652600 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial ST-segment resolution (30%-70%)
Number of subjects: 2484
Study 23652600 — intervention group
Group type: EXPERIMENTAL
Intervention: Absent ST-segment resolution (<30%)
Number of subjects: 2484
Study 21295433 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized self-monitoring with Basic feedback
Number of subjects: 120
Study 21295433 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced behavioral feedback
Number of subjects: 120
Study 21295433 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 120
Study 19299239 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg/day orally)
Number of subjects: 130
Study 19299239 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane (25 mg/day orally)
Number of subjects: 130
Study 17534819 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical levofloxacin (three times on the day before surgery and seven times on the day of surgery)
Number of subjects: 36
Study 17534819 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral levofloxacin (200 mg twice on the day before surgery and 200 mg at 3 hours before surgery)
Number of subjects: 36
Study 17534819 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined topical and oral levofloxacin (according to the above schedules)
Number of subjects: 36
Study 15486815 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg acarbose three times a day for eight weeks
Number of subjects: 20
Study 15486815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11600560 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride infusion
Number of subjects: 20
Study 11600560 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 20
Study 9844752 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light (BL; 5000-8000 lux) for 2 weeks
Number of subjects: 22
Study 9844752 — intervention group
Group type: COMPARATOR
Intervention: Dim light (DL; 300 lux) for 2 weeks
Number of subjects: 22
Study 7863754 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who did not attend treatment regularly (36 patients)
Number of subjects: 1175
Study 7863754 — intervention group
Group type: COMPARATOR
Intervention: Patients who attended treatment regularly but had missed at least one treatment (50 patients)
Number of subjects: 1175
Study 2771867 — intervention group
Group type: EXPERIMENTAL
Intervention: flunitrazepam 1 mg
Number of subjects: 5
Study 2771867 — intervention group
Group type: EXPERIMENTAL
Intervention: triazolam 0.25 mg
Number of subjects: 5
Study 2771867 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 5
Study 782651 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 74
Study 782651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 31746642 — intervention group
Group type: EXPERIMENTAL
Intervention: Lip repair and soft palate closure at 4 months and hard palate closure at 12 months (Arm A)
Number of subjects: 112
Study 31746642 — intervention group
Group type: COMPARATOR
Intervention: Closure of both the soft and hard palate at 12 months (Arm C)
Number of subjects: 112
Study 31746642 — intervention group
Group type: EXPERIMENTAL
Intervention: Finnish center
Number of subjects: 112
Study 31746642 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish centers
Number of subjects: 112
Study 30644326 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole (agonist)
Number of subjects: 0
Study 30644326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30644326 — intervention group
Group type: COMPARATOR
Intervention: Amisulpride
Number of subjects: 0
Study 28160101 — intervention group
Group type: EXPERIMENTAL
Intervention: Low interference group (blocked observation)
Number of subjects: 3
Study 28160101 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium interference group (semi-interleaved observation)
Number of subjects: 3
Study 28160101 — intervention group
Group type: EXPERIMENTAL
Intervention: High interference group (interleaved observation)
Number of subjects: 3
Study 26450585 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-item version of the Questionnaire about the Process of Recovery (QPR)
Number of subjects: 487
Study 26450585 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-item version of the Questionnaire about the Process of Recovery (QPR)
Number of subjects: 487
Study 22981241 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate 10 mg for 60 days
Number of subjects: 96
Study 22981241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 20212518 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (SSRI)
Number of subjects: 811
Study 20212518 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline (tricyclic antidepressant)
Number of subjects: 811
Study 20212518 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HTTLPR and STin4 polymorphisms
Number of subjects: 811
Study 18564168 — intervention group
Group type: EXPERIMENTAL
Intervention: Nissen fundoplication
Number of subjects: 20
Study 16414143 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine and ramipril added to previous antihypertensive treatment for 12 weeks
Number of subjects: 21
Study 16414143 — intervention group
Group type: COMPARATOR
Intervention: Moderate SBP controlled group (n = 10)
Number of subjects: 21
Study 14505816 — intervention group
Group type: EXPERIMENTAL
Intervention: Food restriction (FR)
Number of subjects: 13
Study 14505816 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased physical activity (EX)
Number of subjects: 13
Study 14505816 — intervention group
Group type: COMPARATOR
Intervention: Food restriction (FR) and increased physical activity (EX)
Number of subjects: 13
Study 11020618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intacs implantation
Number of subjects: 359
Study 11020618 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated fellow eyes)
Number of subjects: 359
Study 8866086 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifurcated expanded polytetrafluoroethylene graft (group I)
Number of subjects: 16
Study 8866086 — intervention group
Group type: COMPARATOR
Intervention: Collagen‐impregnated knitted Dacron graft (group II)
Number of subjects: 16
Study 1740491 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 (1 mg/day, orally) for 5 or 15 days
Number of subjects: 0
Study 1740491 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (5-10 mg/day, im, for 2 days) added after RU 486
Number of subjects: 0
Study 1740491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10268816 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling plus rehearsal (treatment group)
Number of subjects: 292
Study 10268816 — intervention group
Group type: COMPARATOR
Intervention: Pamphlets addressing breast cancer and BSE (comparison group)
Number of subjects: 292
Study 31318460 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1
Number of subjects: 1095
Study 31318460 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1+pertuzumab
Number of subjects: 1095
Study 31318460 — intervention group
Group type: COMPARATOR
Intervention: HT (trastuzumab plus taxane)
Number of subjects: 1095
Study 31318460 — intervention group
Group type: COMPARATOR
Intervention: HT
Number of subjects: 1095
Study 29241520 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia-specific training program for nurses using a mobile phone applet, details on dosage and duration not specified.
Number of subjects: 0
Study 29241520 — intervention group
Group type: COMPARATOR
Intervention: Care training for older people with disability (control group).
Number of subjects: 0
Study 25543068 — intervention group
Group type: EXPERIMENTAL
Intervention: dV-Trainer
Number of subjects: 20
Study 25543068 — intervention group
Group type: COMPARATOR
Intervention: da Vinci robot
Number of subjects: 20